Jilin Huinan Changlong Bio-Pharmacy announces shareholder meeting

• Jilin Province Huinan Changlong Bio-Pharmacy scheduled 2025 annual general meeting in Tonghua, Jilin Province on June 9, 2026.
• Shareholders set to vote on 2025 audited consolidated financial statements, directors’ report, independent auditor’s report.
• Meeting to consider supervisory committee report for year ended Dec. 31, 2025.
• Agenda includes reappointment of Prism Hong Kong as auditor for 2026, with board authorized to set remuneration.
• Resolutions cover director and supervisor remuneration for 2026, board and supervisory committee elections through 2029, appointments of three executive directors and one supervisor, general mandate to issue up to 20% of Domestic Shares and 20% of H Shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jilin Province Huinan Changlong Bio-Pharmacy Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260424-12123421), on April 24, 2026, and is solely responsible for the information contained therein.